Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Research

| More

Maintain Buy on Cipla - Positive outlook reaffirmed - HDFC Securities

Posted On: 2020-05-18 11:44:51


Mr. Bansi Desai, Institutional Research Analyst, HDFC Securities.

Cipla (Q4FY20): Positive outlook reaffirmed. Maintain Buy
(TP Rs 655, CMP Rs 570, MCap Rs 460bn)

Cipla's Q4 revenues came in line, however, margins missed estimates on account of Covid led disruption and remediation cost for Goa plant. The outlook for key businesses remains strong with US likely to see improved traction on account of ramp up in gProventil and limited competition launches. India growth trajectory has improved (double digit growth in last 3 quarters) and with enhanced focus (implementation of One-India strategy), domestic growth should outperform the market. Cipla's balance sheet further improved with reduction in net debt (Rs8bn) and improvement in working capital days. We believe with healthy earnings growth (~22% CAGR) and core ROCE expansion (~350bps) over FY20-22e, valuations are likely to re rate. We maintain Buy rating and increase our TP to Rs655 based on 22x FY22 EPS.

Inline revenues, margins disappoint: Revenues at Rs43.7bn came in line as strong growth in India (+12% YoY) offset muted performance in US (-25%YoY, -11% QoQ, gSensipar in base), South Africa (+4% YoY, currency impact) and EMs (+2% YoY, logistics impact). EBIDTA margins at 14.5% were impacted due to deferment of sales (Rs 2bn) and remediation cost for Goa. Adjusted for these, margins came at 16.5%, yet lower than our estimates.

India biz to outperform Industry growth: Cipla's One-India strategy to combine its domestic biz verticals - trade generics, prescription biz and consumer health will lead to strong synergies across the portfolio. They have successfully transitioned select brands with high consumerization potential to consumer division from trade generics.

Respiratory franchise boosted by another complex filing: Besides gAdvair (filing imminent), gProventil (launched), partnered product (undergoing phase III trials), Cipla filed for another complex inhaler in the US (IP protected) with launch timelines of 24-30months. This along with limited competition launches and specialty portfolio (IV Tramadol, Zemdri) will drive near to medium term growth in the US.

Key call takeaways: a) Price erosion stabilised, although deflation continues; b) gProventil - has adequate capacity for fair share, pricing remains attractive; c) Other expenses to moderate with lower promotion spend and R&D costs; d) India growth - no panic signal yet, trade has sufficient inventory; e) Guides for further expansion of ROCE over 3-5 years.

Downside risks: Lower-than-expected growth in India, delay in key US approvals, delay in resolution of Goa plant, higher price erosion in the US.

Shares of CIPLA LTD. was last trading in BSE at Rs.570.2 as compared to the previous close of Rs. 569.6. The total number of shares traded during the day was 360013 in over 8314 trades.

The stock hit an intraday high of Rs. 585 and intraday low of 565.9. The net turnover during the day was Rs. 206554749.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

IPO Review - Computer Age Management Services - ICICI Securities

Company Update - EIH Ltd - ICICI Securities

Gladiator Stocks - Godrej Properties - ICICI Securities

Company Update - Dr Reddy's Laboratories - ICICI Securities

Gladiator Stocks: Pharma Thematic - ICICI Securities

Company Update - Housing & Urban Development - ICICI Securities

Covid Recovery Pulse - E-Way bill generation shows recovery signs with auto volumes flat - ICICI Securities

Quant Pick - UltraTech Cement - ICICI Securities

Lupin & Cipla - Positive News - Angel Broking

Sterling and Wilson Solar Ltd - 106.71 MW order win - Angel Broking

Dr. Reddy's Laboratories - Settles Revlimid litigation in US - ICICI Securities

Natco Pharma - Natco to launch first generic Revlimid - ICICI Securities

Solar Industries - Overseas and defence key to profitability - ICICI Securities

Federal Bank - Strengthening liability muscle; fees & charges revised upwards - ICICI Securities

HCL Technologies Mr. Jyoti Roy, DVP - Equity Strategist, Angel Broking Ltd

CAMS - IPO Note - YES SECURITIES

I-direct Instinct - Intellect Design Arena

P&G Health - Company Update - ICICI Securities

Relaxo Footwears - Mr. Amarjeet Maurya- AVP - Mid Caps, Angel Broking Ltd

Bata India - Mr. Amarjeet Maurya- AVP - Mid Caps, Angel Broking Ltd

Listing of Happiest Minds Technologies - Angel Broking

Dr. Reddy's Lab - Sep 17, 2020 - Angel Broking

VA Tech Wabag - Uphill task ahead; dilution at discount valuation - ICICI Securities

Polymer price tracker - PVC price hikes continue unabated - ICICI Securities

Brigade Enterprises - Resilience amid turbulence - ICICI Securities

Apollo Hospitals Enterprises - Recovering well from COVID-19 impact - ICICI Securities

NTPC - Sustainability targets encouraging - ICICI Securities

Gladiator Stocks - Oberoi Realty - ICICI Securities

Gladiator Stocks - Automotive Axles - ICICI Securities

Quant Pick - IDFC First Bank - ICICI Securities

Company Update - Jammu & Kashmir Bank - ICICI Securities

India Aviation Data - August 2020 - Angel Broking

Shree Cement - Higher volumes to offset lower prices - ICICI Securities

Apollo Hospitals - Q1FY21 Result Update - ICICI Securities

Refining & marketing - Oil price fall boosted GRMs, to push marketing margins up - ICICI Securities

Mr. Deepak Jasani, Head of Retail Research views on FICCI National Executive Committee Meeting with Reserve Bank of India Governor Shaktikanta Das

India trade deficit for August 2020 - Angel Broking

Chemcon Chemicals IPO - Mr. Keshav Lahoti - Associate Equity Analyst, Angel Broking Ltd

CAMS IPO - Mr. Jaikishan Parmar - Sr. Equity Research Analyst, Angel Broking Ltd

August 2020 Trade Data - Acuité Ratings & Research

Wim Plast - Q1FY21 Result Update - ICICI Securities

Company Update - Mishra Dhatu Nigam - ICICI Securities

Stock Tales - Laurus Labs - ICICI Securities

Stock Tales - Granules India - ICICI Securities

Stock of the day - Chalet Hotel - Target INR 200 - Angel Broking

Upgrade to ADD on Dr. Reddy's Labs - Improved visibility in the US business - HDFC Securities

Monetary Policy post CPI inflation numbers for August 2020 - Angel Broking

HUDCO - Q1FY21 Result Update - Angel Broking

Update on Steriscience pharma - Angel Broking

Covid-19 vaccine development by AstraZeneca - Angel Broking







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019